Noticias de la compañía
Good news! FarmaSino was selected into the list of the first batch of pilot enterprises for domestic and foreign trade integration in Jiangsu Province!
Jan 11,2023

Recently, the Department of Commerce of Jiangsu Province announced the list of pilot enterprises for domestic and foreign trade integration, and FarmaSino was successfully selected into the list of pilot enterprises for domestic and foreign trade integration in Jiangsu Province, and a total of 21 enterprises in Nanjing were selected.





The pilot work of Jiangsu Provincial Department of Commerce to carry out domestic and foreign trade integration enterprises is based on the requirements of the Notice of 14 Departments including the Ministry of Commerce on Carrying out the Pilot Project of Domestic and Foreign Trade Integration and the Notice of the Provincial Department of Commerce on Carrying out the Pilot Work of Domestic and Foreign Trade Integration Enterprises, and after the results of independent declaration by enterprises, local review and recommendation and credit review, it aims to improve the development level of domestic and foreign trade integration of market entities and enhance the ability to make overall use of two markets and two resources.




The selection of the first batch of pilot enterprises for the integration of domestic and foreign trade in Jiangsu Province is a recognition of the integrated development and construction of domestic and foreign trade of Kaiyuan Pharmaceutical.FarmaSinohas been focusing on the international business of pharmaceutical and health products, its products are sold to more than 120 countries and regions, and it has an international vision to grasp the most cutting-edge information of massive biomedicine, so as to find upstream and downstream industrial opportunities in the field of domestic medicine and health, layout the fields of pharmaceutical research and development and pharmaceutical production, and take shape of domestic and foreign trade integration.




In the future, FarmaSino will take the selection of the pilot as an opportunity to increase the development of cross-border e-commerce business around the pilot task, continue to increase investment in pharmaceutical R&D and production base, make use of unique resource advantages, realize the integration of resources in domestic and foreign markets, and promote the integration of domestic and foreign trade in Jiangsu with high quality.

FarmaSino Co., Ltd. is a member of Jiangsu Huihong International Group (stock code: 600981), one of the top 500 companies in China, mainly engaged in the internationalization of biomedicine, and its products are sold in more than 120 countries and regions around the world. With an annual export volume of more than 200 million US dollars and annual sales of nearly 1.5 billion yuan, the company has been awarded the "Top 10 Export Enterprises of Western Patent Medicine" by the China Medical Insurance Chamber of Commerce for 9 consecutive years and among the "Top 100 Chinese Pharmaceutical Internationalization Enterprises" for 6 consecutive years. In 2017, the company was successfully elected as the vice president unit of China Chamber of Commerce for Import and Export of Medicines and Health Products. With high-quality products, advanced technology and high-end services, New Century Pharmaceutical makes unremitting efforts to promote the development of China's pharmaceutical industry and build an international biopharmaceutical enterprise integrating R&D, production and international trade.



FarmaSino Co., Ltd. is a wholly-owned subsidiary of FarmaSino Co., Ltd., providing one-stop technical services for the R&D and registration of generic drugs and innovative drugs, establishing industry-university-research cooperation with many universities and scientific research units such as China Pharmaceutical University and Nanjing University of Chinese Medicine, and reaching strategic cooperation with Sinopharm Group, Guangzhou Pharmaceutical Group, Guobang Pharmaceutical Group, Dingtai Pharmaceutical Research Group, etc. In 2021, the company obtained the B certificate of "Drug Manufacturing License" as a marketing authorization holder (MAH). The company has won the national "high-tech enterprise" certification, CNAS laboratory accreditation, national intellectual property management system certification, established Jiangsu Province enterprise graduate workstation, and won the honorary titles of Jiangsu Top 100 Science and Technology Service Institutions, Nanjing Engineering Technology Research Center for Consistency Evaluation of Generic Drugs, Nanjing Engineering Research Center, Nanjing Credit Management Demonstration Enterprise and so on.

Vuelve
PÓNGASE EN CONTACTO
La cooperación conduce a un futuro brillante.
VISÍTENOS
EDIFICIO 5, NO.9 WEIDI CAMINO, QIXIA, NANJING (210033), CHINA
CONTÁCTENOS
0086-25-86907227
yhy@farmasino.com